JOSD2 and non-small cell lung carcinoma: Given the facts that: (1) JOSD1 expression was unrelated with the prognosis of NSCLC patients (Supplementary Fig. S1d); (2) JOSD1 depletion only induced a marginal reduction of cell proliferation (Supplementary Fig. S9e, f), we were encouraged to speculate that the anticancer activities of HY041004 may largely owing to its JOSD2-targeting effect.